Tuesday, April 20, 2021
10:43 AM EST – Resverlogix Corp. : Announced today the publishing of an article titled: “Bromodomain and extraterminal protein inhibitor, apabetalone (RVX-208), reduces ACE2 expression and attenuates SARS-CoV-2 infection in vitro”, in Biomedicines, a high-impact scientific journal. The previously announced findings , made in collaboration with Dr. Dalia ElGamal’s research group at the University of Nebraska Medical Center (UNMC), Omaha, Nebraska, have completed the peer-review process. Resverlogix Corp. (T.RVX) shares were up $0.02 at 0.89.
Stocks in Play: Resverlogix Corp., Tue, 20 Apr 2021 10:57:05 EST